Best Practice & Research Clinical Haematology

Papers
(The TQCC of Best Practice & Research Clinical Haematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation79
The role of randomized controlled trials, registries, observational databases in evaluating new interventions49
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes43
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program38
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL38
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances25
Endpoint selection and evaluation in hematology studies25
Coagulopathy in COVID-19 and anticoagulation clinical trials25
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)24
Editorial Board23
The presentation of results from studies in clinical haematology23
Take a spin: Apheresis in the care of adult leukaemia patients22
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms15
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma15
Creating a GMP cell processing program: A focus on quality and regulation14
Vaccine-induced immune thrombotic thrombocytopenia14
Targeted cellular therapy for treatment of relapsed or refractory leukemia12
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults11
What should be done and what should be avoided when comparing two treatments?11
Principles of cost-effectiveness studies and their use in haematology11
The international cooperative Gaucher group (ICCG) Gaucher registry11
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”11
Editorial Board10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma10
Dysregulation of Protein S in COVID-1910
The role of registries in hematological disorders9
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment8
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma8
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?8
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration8
Anti-GM-CSF autoantibodies in myeloid leukemias8
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders8
Handling missing covariate data in clinical studies in haematology7
A reflection on Arnold Caplan, the father of MSC7
Editorial Board / Aims & Scope7
Recent progress in acute leukemia and myelodysplasia7
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies7
CAR assembly line: Taking CAR T-cell manufacturing to the next level7
0.6368510723114